Summary

• The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.
• Please refer to the local labeling for information on drug interactions with IMAAVY.

PRESCRIBING INFORMATION

DRUG INTERACTIONS

Effect of IMAAVY on Other Drugs

• Concomitant use of IMAAVY with medications that bind to the human neonatal Fc receptor (FcRn) (e.g., immunoglobulin products, monoclonal antibodies, or antibody derivates containing the human Fc domain of the IgG subclass) may lower systemic exposures and reduce effectiveness of such medications.¹ 
• Closely monitor for reduced effectiveness of medications that bind to the human FcRn. When concomitant long-term use of such medications is essential for patient care, consider discontinuing IMAAVY, and using alternative therapies.¹ 

PHARMACOKINETICS

Drug Interactions with Other Drugs or Biological Products

IgG-Based Monoclonal Antibodies

• Nipocalimab decreases concentrations of compounds that bind to the human FcRn, including IgG based monoclonal antibodies.¹ 

Cytochrome P450 Enzymes

• Nipocalimab is not metabolized by cytochrome P450 enzymes; therefore, interactions with concomitant medications that are substrates, inducers, or inhibitors of cytochrome P450 enzymes are unlikely.¹ 

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) conducted on 27 April 2025 did not identify any relevant citations pertaining to this topic.